Author: Willem van Lawick

Leiden, The Netherlands, 22 June 2012 – Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has won the Emerging Star accolade at last night’s European Mediscience Awards.

Groningen, The Netherlands, 10 May 2012, Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mimopath®-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.

Groningen, The Netherlands, 3 May 2012, Dutch biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal Vaccine of preclinical data showing that FluGEM® provides superior cross-protection against influenza virus. FluGEM® is a new Mimopath®-based mucosal influenza vaccine that can be administered through simple droplets in the nose.

Ghent, Belgium, 16 March 2012, Pronota NV, the developer of first-in-class diagnostics for early detection of life-threatening conditions, has appointed Carol Greve-Philips as Chief Business Officer and Els Hubloux as Chief Financial Officer.

Leiden, The Netherlands, 25 January 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life… Continue reading Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates